Investor Presentaiton

Ongoing Investment in Newer Portfolios Worth over $ 180 bn Current Business One of the leading players in Indian pharma industry and a strong player in global generics market Mid term Biogenerics : 40 bn Transdermal : 10 bn : 22 bn : 16 bn Long term Novel discovery products from Zydus NME pipeline Near term Pulmonary : 20 bn Vaccine Topical Transdermal : 10 bn Injectables Oncology : 17 bn : 55 bn Note: Value indicated is estimated brand sale ($) 17

View entire presentation